Work

Abstract 7747: Comparison of T-cell activation status in patients treated with retifanlimab in combination with anti-LAG3/Anti-TIM3 vs retifanlimab alone

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-7747

Authors: Robert I. Haddad, Denis Soulières, Prakash Neupane, Amaury Daste, Zhiwan Dong, Jin Lu, Michelle Kinder, Jeff Jackson, Richard Schaub, Nawel Bourayou, John Janik, Christophe Le Tourneau

Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center, Centre Hospitalier de l’Université de Montréal, University of Kansas Medical Center, Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Incyte (United States), Institut Gustave Roussy

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148770784

Cites:

Cited by:

Related to: